The intersection between the KEAP1 methylation event and the EGFR mutant/KRAS wild-type status suggests a possible translational impact in terms of shorter overall survival and clinical benefit to chemotherapeutic and targeted biological treatments of patients with NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.